Axcellant will participate in the Annual Congress of the European Association of Nuclear Medicine (EANM 2026), taking place from 17 to 21 October 2026 in Vienna, Austria. The event brings together experts, researchers and industry leaders to discuss the latest advances in nuclear medicine, molecular imaging, radiopharmaceutical development and theranostics.
As a specialist CRO for radiopharmaceutical development and imaging, Axcellant supports pharmaceutical and biotechnology companies in translating scientific innovation into robust clinical evidence.
With expertise spanning clinical trial management, Imaging Core Lab services, regulatory strategy and clinical operations, Axcellant provides specialised support throughout the clinical development process. The company’s integrated approach combines scientific expertise with operational excellence to address the unique challenges of radiopharmaceutical and imaging-based clinical trials.
EANM 2026 provides an important opportunity to exchange knowledge, explore emerging trends and discuss the evolving needs of clinical development in nuclear medicine.
Representing Axcellant in Vienna will be:
During the congress, the Axcellant representatives look forward to connecting with pharmaceutical and biotechnology companies, researchers and potential partners to discuss clinical development challenges and opportunities for collaboration.
Attending EANM 2026? Connect with Michał Dyśko or Jan Rezulski to arrange a meeting and learn how Axcellant can support your radiopharmaceutical development and imaging projects.
3 Questions with: Prof. Piotr Słomka Large language models are entering nuclear cardiology at a pace that makes the usual…
How Axcellant helped a diagnostic study overcome isotope supply, manufacturing, and logistics constraints In radiopharmaceutical development, we often say that…
Europe’s clinical trials market is entering a more practical phase in its approach to competitiveness. With the Clinical Trials Regulation…
Copyright @ 2026 Axcellant